NICE approves Pazopanib for kidney cancer24th February 2011
The National Institute for Health and Clinical Excellence has approved a new treatment for kidney cancer.
The NHS drugs advisory body has recommended Pazopanib as a first-line treatment for those with advanced kidney cancer in certain circumstances. It has also been recommended for patients who have not previously had cytokine therapy and either remain active or only struggle with strenuous activity. Manufacturer GlaxoSmithKline has agreed a discount on the list price with a possible future rebate linked to the outcome of a clinical trial.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: NICE approves Pazopanib for kidney cancer
Author: Mark Nicholls
Article Id: 17683
Date Added: 24th Feb 2011